Europska Unija - hrvatski - EMA (European Medicines Agency)

intervet international b.v. - cellular " potpomognuta živa рекомбинантная turske герпесвирус (soj hvp360), izražavajući sintezu proteina virusa nd i vp2 s proteinima virusa ИБД - ptica virus herpesa (bolest Марека) + ptičji virus infektivne бурсальной bolesti (bolest Гамборо) + virusa ньюкаслской bolesti/парамиксовируса - chicken; embryonated chicken eggs - for active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (ibd) virus,to reduce mortality, clinical signs and lesions caused by marek’s disease (md) virus.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastična sredstva - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastična sredstva - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastična sredstva - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

beckman coulter d.o.o., zagreb - in vitro dijagnostički sistem, hematološki brojač, analizator

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

intervet international b.v., podružnica u rh, ivana lučića 2a, 10000 zagreb, republika hrvatska - inaktivirana lawsonia intracellularis, soj spah-08 - liofilizat i otapalo za emulziju za injekciju, za svinje - svinja

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

intervet international b.v., podružnica u rh, ivana lučića 2a, 10000 zagreb, republika hrvatska - inaktivirana lawsonia intracellularis, soj spah-08 - liofilizat i otapalo za emulziju za injekciju - svinja

Europska Unija - hrvatski - EMA (European Medicines Agency)

eco animal health europe limited - tylvalosin - Противоинфекционные za sistemsku upotrebu antibakterijski lijekovi za sistemsku upotrebu makrolidi - pheasants; chicken; turkeys; pigs - pigstreatment i methaphylaxis svinja энзоотической upale pluća;liječenje svinjske пролиферативной энтеропатии (ileitis);liječenje i methaphylaxis dizenterija svinja. chickenstreatment i methaphylaxis respiratorne bolesti povezanih s галисептикум микоплазмоза kod pilića. pheasantstreatment respiratorne bolesti povezanih s галисептикум микоплазмы . turkeystreatment respiratorne bolesti povezanih s tylvalosin osjetljivih sojeva ornithobacterium rhinotracheale u purana.

Europska Unija - hrvatski - EMA (European Medicines Agency)

bayer ag - sorafenib - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastična sredstva - Гепатоцеллюлярная carcinomanexavar indiciran za liječenje karcinoma гепатоцеллюлярной. Почечно-stanični carcinomanexavar indiciran za liječenje bolesnika s prevladava почечно-stanica karcinoma, koji nisu ranije interferona-alfa ili interleukina-2 terapije ili se smatraju neprikladnim za takve terapije. diferencirani štitnjače carcinomanexavar indiciran za liječenje bolesnika s прогрессирующим, lokalno-uobičajena ili metastaze, diferencira (папиллярный/фолликулярный/hürthle staničnog) rak štitnjače, рефрактерным na konstanta Йоду.